Stock Events

Stock Events

Hemostemix 

$0.035000
6
-$0.00-1.89%Friday 14:30

Statistics

Day High
0.035
Day Low
0.035
52W High
0.07618
52W Low
0.035
Volume
19,000
Avg. Volume
5,895
Mkt Cap
7.17M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 27Expected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.39MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HMTXF. It's not an investment recommendation.
Telus
2
T.TO
Air Canada
2
AC.TO
Whitecap Resources
2
WCP.TO
Brompton Split Banc
2
SBC.TO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap167.52B
Pfizer is involved in the development of drugs and therapies, including those in the regenerative medicine space, competing with Hemostemix's stem cell therapies.
Novartis
NVS
Mkt Cap307B
Novartis focuses on innovative medicines and directly competes in the regenerative medicine sector, offering alternatives to Hemostemix's solutions.
Gilead Sciences
GILD
Mkt Cap207B
Gilead Sciences is a biopharmaceutical company that develops treatments for various conditions, including those that could compete with stem cell therapies offered by Hemostemix.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.85B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and has interests in developing treatments that could compete with Hemostemix's stem cell-based therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.71B
Vertex Pharmaceuticals engages in creating new therapies, including those in the regenerative medicine area, potentially competing with Hemostemix.
CRISPR Therapeutics
CRSP
Mkt Cap4.86B
CRISPR Therapeutics is focused on gene editing, a revolutionary approach that competes with traditional stem cell therapies offered by Hemostemix.
Editas Medicine
EDIT
Mkt Cap394.7M
Editas Medicine is involved in gene editing, directly competing with the stem cell therapy market that Hemostemix is part of.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics is another key player in the gene editing space, offering competitive alternatives to stem cell-based therapies like those developed by Hemostemix.

About

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Show More
CEO
Thomas A. Smeenk
Employees
12
Country
Canada
ISIN
CA4236943060
WKN
000A2QQGU

Listings

STU
DE
2VF0.STU
OTC Link
US
HMTXF
V
CA
HEM.V
F
DE
2VF0.F

0 Comments

Share your thoughts

FAQs

What is Hemostemix stock price today?▼
The current price of HMTXF is $0.04 USD — it has decreased by -1.89% in the past 24 hours. Watch Hemostemix stock price performance more closely on the chart.
What is Hemostemix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Hemostemix stocks are traded under the ticker HMTXF.
Is Hemostemix stock price growing?▼
HMTXF stock has fallen by -14.4% compared to the previous week, the month change is a -19.48% fall, over the last year Hemostemix has showed a -44.44% decrease.
What is Hemostemix market cap?▼
Today Hemostemix has the market capitalization of 7.17M
When is the next Hemostemix earnings date?▼
Hemostemix is going to release the next earnings report on November 27, 2026.
What is Hemostemix revenue for the last year?▼
Hemostemix revenue for the last year amounts to 0 USD.
What is Hemostemix net income for the last year?▼
HMTXF net income for the last year is -3.39M USD.
How many employees does Hemostemix have?▼
As of November 9, 2026, the company has 12 employees.
In which sector is Hemostemix located?▼
Hemostemix operates in the Health & Wellness sector.
When did Hemostemix complete a stock split?▼
The last stock split for Hemostemix was on December 30, 2020 with a ratio of 1:20.
Where is Hemostemix headquartered?▼
Hemostemix is headquartered in Calgary, Canada.